Trade Biogen Inc. - BIIB CFD

Trading Conditions

• Type:
  CFD

  

  Knock-out

  
• Spread: 0.49
• Long position overnight funding adjustment: -0.02160%
• Short position overnight funding adjustment: -0.00063%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 180.51
• Open: 183.6
• 1-Year Change: 54.61%
• Day's Range: 181.88 - 183.6

Trade Biogen Inc. - BIIB CFD

Biogen Inc. (BIIB) is a biotechnology company in the field of neurological and neurodegenerative diseases. 

Established in 1978 and headquartered in Cambridge, Massachusetts, Biogen has devoted its scientific research to defeating neurological diseases, like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). 

With the aid of some of the world’s leading neuroscientists and neurologists, Biogen has sought treatments against common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP). 

The use of advanced technologies and engineering skills has enabled Biogen to bring effective medicines to the market. The company’s products include SPINRAZA for the treatment of SMA; TECFIDERA, AVONEX, FAMPYRA, VUMERITY and TYSABRI for multiple sclerosis; ADUHELM for Alzheimer’s disease; and FUMADERM for the treatment of severe plaque psoriasis.

Biogen has made an agreement with Genentech, a member of the Roche Group for business and financial rights, with respect to RITUXAN, GAZYVA and OCREVUS. It’s constantly looking at ways to improve its research and development to compete against other biotech giants like Pfizer Inc (PFE), Johnson & Johnson (JNJ) and Amgen (AMGN). 

Biogen went public in September 1991. It trades on the Nasqaq under the ticker ‘BIIB’.